Morning reading 丨 July 27th, pay attention to health every day

【Health Reminder】

Consuming super-processed foods increases the risk of cancer

A study published in the British Medical Journal confirmed that a 10% increase in intake of super-processed foods may increase the overall cancer risk by 12% and the risk of breast cancer by 11%.

The study followed more than 100,000 French adults with an average age of 42.8 ± 14.8 years between 2009 and 2017. The researchers analyzed the results and found that young people, smokers, people with less education, no physical activity, and no family history of cancer consumed more super-processed foods. The analysis showed that a 10 percent increase in ingestion of super-processed foods increased the overall risk of cancer development, an 11 percent increase in breast cancer risk, and a 13 percent increase in breast cancer risk in postmenopausal women.

【Medical Exploration】

Men are more affected by their spouse's cardiovascular disease

A study published in Circulation, Cardiovascular Quality and Prognosis confirmed that a spouse with a history of cardiovascular disease increased their risk of cardiovascular events by 48 percent.

The researchers selected 13,759 residents whose spouses had a history of cardiovascular disease and paired them with 55,027 people whose spouses had no history of cardiovascular disease. During the average 95-month follow-up period, the incidence of serious cardiovascular events was 0.6% for spouses with a history of cardiovascular disease. If the spouse has a history of cardiovascular disease, the risk of serious cardiovascular events in women and men increases by 22% and 68%, respectively. The study suggests that men's risk of cardiovascular events is more affected by their spouses, possibly because men are habitually dependent on their wives for a "common lifestyle."

【Drug Progress】

Beda Pharmaceuticals ensartinib intends to be reviewed on a priority basis

According to the announcement of the Drug Evaluation Center of the State Food and Drug Administration, the ALK inhibitor ensartinib of Beida Pharmaceutical was included in the proposed priority review, which is the first domestic class 1 new drug for the treatment of advanced non-small cell lung cancer with ALK mutation.

Ensartinib, jointly developed by Beida Pharmaceuticals and its holding subsidiary Xcovery, has completely independent intellectual property rights, and is a new powerful and highly selective new generation of anaplastic lymphoma kinase (ALK) inhibitor for the treatment of patients with locally advanced or metastatic non-small cell lung cancer with anaplastic lymphoma kinase positive. In November 2020, ensartinib was approved for listing in China, becoming another major layout product of Beida Pharmaceutical in the field of lung cancer after EGFR-TKI.

【Scientific Diet】

In the summer, the spleen is moist, try two kinds of health porridge

"A summer without disease and three points of weakness", in the hot summer, most of people's spleen and stomach are in a weak state, and they need to be maintained. Zhu Yanghua, deputy chief physician of the Department of Traditional Chinese Medicine Rehabilitation of Hunan Yongzhou Central Hospital, reminded that summer food supplements are heavy in the healthy spleen and dampness, and you can try health porridge.

Yam goji berry porridge: take 150 grams of japonica rice, 200 grams of yam, 50 grams of goji berries, an appropriate amount of sugar, simmer for 30 minutes to form a porridge. This porridge is soft and refreshing, can eliminate fatigue, blood and eyesight. Guiyuan corn porridge: 15 grams of cinnamon meat, 100-200 grams of corn. After washing, the two are boiled together, first boiled over a low flame, and then boiled over low heat to form porridge. Cinnamon meat has a sweet and warm taste, which can nourish the heart and spleen, nourish the blood and calm the spirit.

【Knowledge Update】

Long-term use of PPIs increases the risk of colorectal cancer

Gut published a new study in which the duration of use of proton pump inhibitors (PPIs) was associated with an increased risk of colorectal cancer.

The study included more than 1.2 million proton pump inhibitor users and nearly 300,000 histamine 2 receptor inhibitor users, with a median follow-up of 4.9 years. The researchers found that the use of proton pump inhibitors in any form compared to histamine 2 receptor inhibitors was not associated with the onset of colorectal cancer. However, increased cycles and doses of proton-pump inhibitors are associated with an increased risk of colorectal cancer. In particular, cumulative use of proton pump inhibitors for 4 years or more was associated with a 60% increased risk of colorectal cancer.

Beijing News reporter Zhang Zhaohui

Proofreading Fu Chunyi